Manage stand orders
Select Option
Manufacturers

Medical Products Research srl

Via Novara 68, 20025 Legnano
Italy
Telephone +39 331 597992
Fax +39 331 485089
info@mpr-italy.it

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Media files

Contact

Francesca Serafini

Sales team, business development

Phone
00393771806123

Email
francesca.serafini@mpr-italy.it

Luca Belossi

Sales team, business development

Phone
00393406305624

Email
luca.belossi@mpr-italy.it

Our range of products

Product categories

  • 01  Electromedical equipment / medical technology
  • 01.06  Intense medicine / anesthesiology / respiration
  • 01.06.04  Inhaler and aerosol appliances

Inhaler and aerosol appliances

  • 01  Electromedical equipment / medical technology
  • 01.06  Intense medicine / anesthesiology / respiration
  • 01.06.07  Other equipment for intense medicine / anesthesiology / respiration

Other equipment for intense medicine / anesthesiology / respiration

Our products

Product category: Respiration equipment, oxygen equipment

OUR COMPANY, WHAT WE DO, HOW WE DO IT

Medical Products Research Srl is an Italian manufacturer of medical and electromedical devices for both hospital and home-care market.

Founded in 2005, its head office is in Legnano (Italy) where the devices are entirely designed and developed, to guarantee the “Made in Italy” quality standard.

MPR focuses on respiratory diseases and in particular on airways clearance.

The aim of the company is the continuous research for innovative solutions to develop therapeutic treatments as less-invasive as possible, respecting the physiologic parameters involved in the process of breathing and airways clearance, limiting the contraindications often related to traditional therapies and, as consequence, improving comfort, adherence and effectiveness.

MPR devices are studied to match needs of adult and paediatric, collaborative and non-collaborative patients.

The company owns 2 patents, both recognised at national and international level:

TPEP® (TEMPORARY POSITIVE EXPIRATORY PRESSURE) technology
Patented in 2005, the technology TPEP® (Temporary Positive Expiratory Pressure) aids patients in the removal of bronchial secretions, applying a minimum temporary positive pressure in exhalation needed to counteract the airways collapse without penalising the expiratory flow. This technology, completely non-invasive, has proven to be highly effective in patients suffering from respiratory dysfunction and hypersecretion. Over the years, a number of clinical research studies have demonstrated the effectiveness of the system. Today, TPEP® represents a valid support for respiratory rehabilitation and it has proved to be a good solution for many patients, respecting the organ that is the cause of their problems.

EFA® (EXPIRATORY FLOW ACCELERATOR) technology
In 2009 MPR developed a second patented technology called EFA® (Expiratory Flow Accelerator). This innovative technology accelerates the expiratory flow, promoting deep drainage and secretions removal in patients with ineffective cough, without applying any pressure in the airways. The secretions safely reach the upper airways where the patient can expel or ingest them in a physiological way through the mechanism of the mucociliary system.

TPEP® & EFA® technologies are available in stand-alone devices or integrated in multifunctional equipments specifically studied to help health operators to customize the treatment on each single patient.

More Less

Product category: Respiration equipment, oxygen equipment

KALOS: A COUGH ASSIST OF THE LATEST GENERATION, BUT NOT ONLY..

KALOS cough machine responds to the growing awareness that patients with neuromuscular disorders and problems in managing bronchial secretions need customized treatments based on different techniques.

Integrated with the cough assist function, KALOS is also equipped with EFA® (Expiratory Flow Accelerator) technology for a deep and gentle clearance of the airways, as well as the possibility to perform lung expansion manoeuvres with the Continuous Pressure mode, and the ability to check the effectiveness of the patient’s cough through a digital peak cough flow indicator.

More Less

Product category: Respiration equipment, oxygen equipment

TPEP®4 FOR POST-COVID LUNG EXPANSION AND REHAB

According to expert projections, it is estimated that 30% of patients affected by COVID-19 could have permanent lung damage and very disabling alterations in respiratory function.
In this phase it is essential to intervene with targeted and personalized strategies to restore the best functional conditions and prevent secondary lung damage.
The suggestions of the experts are reported in “Italian suggestions for pulmonary rehabilitation in COVID-19 patients recovering from acute respiratory failure: results of a Delphi process" recently published in the Monaldi Archives for Chest Disease magazine.

TPEP®4 provides the best technology to respond to the suggestions of the experts.
The therapeutic options included, with the possibility of integrating and modulating the different strategies, allow a flexible, personalized and safe treatment. The inspiratory and / or expiratory flow-dependent resistance with adjustable pressure target, the comfortable visual and auditory feedback, allow to guide and assist the patient in the correct execution of what is prescribed by the clinician, even when the therapy must continue independently or remotely .

More Less

Product category: Respiration equipment, oxygen equipment

FREE FLOW: ACTIVE HUMIDIFIER WITH HIGH FLOW GENERATOR AND EXPIRATORY FLOW ACCELERATOR (EFA®)

The administering, by FREE FLOW device, of heated and humidified high-flow air, possibly enriched with oxygen, allows comfortable and controlled oxygen therapy and adequate ventilatory support, as well as ensuring the fluidification of bronchial secretions.

The humidification therapy is complementary to the incorporated EFA® technology, that supports muco-ciliary clearance by facilitating the mobilization and removal of secretions in a non-invasive way.

More Less

Product category: Respiration equipment, oxygen equipment

FLOW KLEANER: BRONCHIAL SECRETIONS SUCTION UNIT INCORPORATED WITH EXPIRATORY FLOW ACCELERATOR (EFA®)

Through a compact and handy design, built-in battery and convenient foldaway handle, FLOW KLEANER ensures an optimal clearance throughout the entire bronchial tree for adult and pediatric patients.

Beside the innovative suction system, EFA® technology allows a deep, safe and comfortable airways clearance, purely by means of expiratory flow acceleration.

EFA® technology decreases the need for intervention with deep aspirations, that often cause discomfort and sometimes are even harmful for the patients.

More Less

Product category: Respiration equipment, oxygen equipment

FREE ASPIRE ADVANCED: DEVICE FOR AIRWAYS CLEARANCE USING EXPIRATORY FLOW ACCELERATOR (EFA®)

FREE ASPIRE ADVANCED is a medical device for non-invasive removal of tracheo-bronchial secretions, designed for adult and paediatric patients with reduced or absent cough capacity.

It employs EFA® (Expiratory Flow Accelerator) patented technology.
Through an acceleration of the expiratory flow, the tracheo-bronchial secretions reach the upper airways, in complete safety and without any contraindications, so allowing the patient to expel them or ingest them if unable to eject them spontaneously.
Therapy with FREE ASPIRE ADVANCED is comfortable and respects the patient’s natural breathing pattern. Patients feel no unpleasant sensation during the therapy.

More Less

Product category: Respiration equipment, oxygen equipment

SUCTION FREE: AIRWAYS CLEARANCE USING EXPIRATORY FLOW ACCELERATOR (EFA®) HOSPITAL EDITION

SUCTION FREE is a medical device for the management of tracheobronchial secretions in hospitalized patients. It is a user-friendly system employing EFA® developed for adult and paediatric, even non-cooperative, patients with reduced or absent cough capacity.

SUCTION FREE is generally employed in the following hospital wards:
• ICU
• Geriatrics
• Oncology
• Stroke Unit
• Neurology
• Heart Surgery
• Thoracic Surgery
• Pulmonology
• ENT
• Neonatology
• Paediatrics

More Less

Company news

Date

Topic

Download

Nov 13, 2020

POST COVID-19 REHABILITATION & TPEP® TECHNOLOGY

SUGGESTIONS OF HEALTHCARE SPECIALISTS

The paper “Italian suggestions for pulmonary rehabilitation in COVID-19 patients recovering from acute respiratory failure: results of a Delphi process” was recently published on Monaldi Archives for Chest Disease journal.
Through the Delphi method, 50 professionals, including representatives of the scientific associations of the field (ARIR, AIPO, SIP, AIFI and SIFIR) and experts of international caliber, carried out a consensus document on pulmonary rehabilitation and respiratory physiotherapy for patients who suffered the acute phase of COVID-19. The aim of the work is providing useful suggestions, based on available scientific evidence and shared between experts, to lead the decision-making process on the individual patient in this new clinical context.

Our TPEP® devices provide the best technology to respond to what is suggested by experts. The therapeutic options included, with the possibility of integrating and modulating the different strategies, allow a flexible, personalized and safe treatment. The inspiratory and / or expiratory flow-dependent resistance with adjustable pressure target, the comfortable visual and auditory feedback, allow to guide and assist the patient in the correct execution of what is prescribed by the clinician, even when the therapy must continue independently or remotely . 

More Less

Nov 12, 2020

THE EFA® TECHNOLOGY IN PARKINSON'S PATIENTS WITH DYSPHAGIA

Parkinson’s disease (PD) can cause swallowing and cough disorders. Oropharyngeal dysphagia is the main cause of pneumonia, that is the leading cause of death in PD. Different strategies exist to reduce the risk of inhalation, but evidence of their efficacy is still unclear.

The clinical study “Effectiveness of accelerating expiratory flow in patients with Parkinson’s disease and swallowing deficiency: a preliminary study“, recently published on “Clinical Neurology and Neurosurgery”, investigates if adding an expiratory flow acceleration (EFA®) technique to standard therapy (ST) for dysphagia can reduce the incidence of bronchopulmonary infections and improve quality of life, respiratory function parameters, cough, and airways encumbrance perception.

This study shows that patients treated with EFA® had less respiratory infections, symptoms, hospital admissions and medical visits. Furthermore, there was a significant difference in cough effectiveness measured with the peak cough expiratory flow (PCEF) and in other respiratory function parameters (FEV1, FVC), and also in specific and generic health-related quality of life measures (PDQ-39, Euro-QoL-VAS).

The results of this preliminary study support the use of EFA® technology in Parkinson’s patients with dysphagia to reduce the risk of respiratory complications.

More Less

Nov 11, 2020

THE EFA® TECHNOLOGY IN TRACHEOSTOMISED PATIENTS

A PILOT STUDY ON THE NON-INVASIVE MANAGEMENT OF TRACHEOBRONCHIAL SECRETIONS IN TRACHEOSTOMISED PATIENTS

Introduction/Objectives:
The aim of our study was to assess the safety, efficacy and feasibility of an Expiratory Flow Accelerator (EFA) device, Free Aspire, in reducing the need for daily suctions in tracheostomised (TCS) patients.

Methods: Twenty‐five patients were investigated.
The number of superficial/deep suctions, shallows, arterial blood gas (ABG) analysis, perception of mucus encumbrance (Visual Numeric Scale, VNS) and adverse event were recorded for five days.
On the first two days, suctioning was performed as usual, on the following three days, patients were treated also with EFA®.

Conclusion: 
EFA® may be useful for managing secretions in TCS patients, as it can reduce the number of daily suctions,  particularly the deep ones, and may improve the perception of mucus encumbrance, without side effects. 

More Less

About us

Company details

Medical Products Research Srl is an Italian manufacturer of medical and electromedical devices for both hospital and home-care market.

MPR focuses on respiratory diseases and in particular on airways clearance.

The aim of the company is the continuous research for innovative solutions to develop therapeutic treatments as less-invasive as possible, respecting the physiologic parameters involved in the process of breathing and airways clearance.

MPR devices are studied to match needs of adult and paediatric, cooperative and non-cooperative patients.

The company owns 2 patents:

  • TPEP® (TEMPORARY POSITIVE EXPIRATORY PRESSURE) technology
  • EFA® (EXPIRATORY FLOW ACCELERATOR) technology

More Less

Company data

Foundation

2005

Area of business

Electromedical equipment / Medical Technology

Company information as a PDF file